"Vincristine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
| Descriptor ID |
D014750
|
| MeSH Number(s) |
D03.132.436.681.827.817 D03.633.100.473.402.681.827.817
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Vincristine".
Below are MeSH descriptors whose meaning is more specific than "Vincristine".
This graph shows the total number of publications written about "Vincristine" by people in this website by year, and whether "Vincristine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 2 | 2 |
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 2 | 2 |
| 2003 | 1 | 0 | 1 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 3 | 3 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 6 | 6 |
| 2009 | 0 | 2 | 2 |
| 2010 | 1 | 3 | 4 |
| 2011 | 0 | 7 | 7 |
| 2012 | 0 | 3 | 3 |
| 2013 | 1 | 5 | 6 |
| 2014 | 1 | 2 | 3 |
| 2015 | 2 | 4 | 6 |
| 2016 | 0 | 4 | 4 |
| 2017 | 1 | 3 | 4 |
| 2018 | 0 | 7 | 7 |
| 2019 | 1 | 7 | 8 |
| 2020 | 3 | 5 | 8 |
| 2021 | 1 | 5 | 6 |
| 2022 | 0 | 5 | 5 |
| 2023 | 0 | 2 | 2 |
| 2024 | 1 | 4 | 5 |
| 2025 | 1 | 3 | 4 |
| 2026 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vincristine" by people in Profiles.
-
Dual enzyme therapy improves adherence to chemotherapy in a patient with gaucher disease and Ewing sarcoma. Pediatr Hematol Oncol. 2023 May; 40(4):422-428.
-
Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms. Blood Cancer J. 2022 02 01; 12(2):25.
-
Rising drug cost impacts on cost-effectiveness of 2 chemotherapy regimens for intermediate-risk rhabdomyosarcoma: A report from the Children's Oncology Group. Cancer. 2022 Jan 15; 128(2):317-325.
-
Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up. Blood Cancer J. 2020 05 04; 10(5):49.
-
Congenital spindle cell rhabdomyosarcoma. Pediatr Blood Cancer. 2019 11; 66(11):e27935.
-
Pharmacogenetic association with neurotoxicity in Hispanic children with acute lymphoblastic leukaemia. Br J Haematol. 2018 06; 181(5):684-687.
-
Clinical Factors Associated with Long-Term Complete Remission versus Poor Response to Chemotherapy in HIV-Infected Children and Adolescents with Kaposi Sarcoma Receiving Bleomycin and Vincristine: A Retrospective Observational Study. PLoS One. 2016; 11(4):e0153335.
-
The Pharmacogenomics of Vincristine-Induced Neuropathy: On Pins and Needles. JAMA Oncol. 2015 Oct; 1(7):975-6.
-
Inpatient versus outpatient vincristine, dactinomycin, and cyclophosphamide for pediatric cancers: Quality and cost implications. Pediatr Blood Cancer. 2015 Nov; 62(11):1925-8.
-
Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys. 2015 May 01; 92(1):113-21.